Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 2NET 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Pituitary Neoplasms 2Pituitary ACTH Hypersecretion 2Prostatic Neoplasms 1Prolactinoma 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Breast Neoplasms 1Adrenocortical Hyperfunction 1Acromegaly 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Cabergoline × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01730729 2019-09-17

Cabergoline in Metastatic Breast Cancer

Northwestern University

Phase EARLY_PHASE1 Completed
20 enrolled 11 charts
Breast

Breast Neoplasms

NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Universidade Federal do Rio de Janeiro

Phase 2/3 Completed
21 enrolled 4 charts

Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡